News

Merck Announces $1.35 Billion Acquisition of Imago BioSciences

November 28, 2022

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement

November 28, 2022

The agreement aims to develop integrated technology for large-scale exosome production.

Ferinject Approved in China for the Treatment of Iron Deficiency in Adult Patients

November 28, 2022

NMPA has approved Ferinject in China for the treatment of iron deficiency or iron deficiency anemia.

ACS-Grade Reagents’ Database Launched

November 28, 2022

The complete online database of ACS Reagent Chemicals is now available.

MilliporeSigma Invests $286 Million in US Drug Safety Testing Capacity

November 22, 2022

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

Regeneron and Cytomx Announce $2 Billion Oncology Collaboration

November 22, 2022

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

Gelomics and Rousselot Biomedical Announce 3D Cell Culture Kits Based on Gelatin Methacryloyl

November 22, 2022

Rousselot Biomedical will supply Gelomics with its gelatin methacryloyl, a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.

Bio-Rad Introduces Pioneer Antibody Discovery Platform for Therapeutic Development

November 22, 2022

The Pioneer Antibody Discovery Platform is a new antibody discovery service specifically designed to develop best-in-class biologic candidates.

FDA Approves Injection Designed to Delay Onset of Type 1 Diabetes

November 21, 2022

Tzield (teplizumab-mzwv) injection is the first FDA-approved therapy designed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older.

FDA Committee Recommends Ardelyx Kidney Disease Drug

November 21, 2022

Initially rejected in July 2021, XPHOZAH (tenapanor) won recommendations as both a monotherapy and combination treatment from FDA’s CRDAC meeting.